INTRODUCTION
Warfarin is a widely used anticoagulant with a narrow therapeutic index and large inter-patient variability in the dose required to achieve target anticoagulation. Common genetic variants in CYP2C9, VKORC1, CYP4F2 and the CYP2C cluster (e.g., rs12777823), plus known non-genetic factors, account for ~50% of warfarin dose variability. This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing and aims to assist in the interpretation and use of CYP2C9, VKORC1, CYP4F2, and rs12777823 genotypes to estimate therapeutic warfarin dose among patients with a target international normalized ratio (INR) of 2-3, should clinical genotype results be available to the clinician. The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institute of Health's Pharmacogenomics Research Network develops peer-reviewed gene/drug guidelines that are published and updated periodically on https://cpicpgx.org/genes-drugs/ and http://www.pharmgkb.org based upon new developments in the field (1) . These guidelines were written with a global audience in mind, although the majority of the data that underpin these guidelines arise from people of European ancestry, East Asia and African Americans.
FOCUSED LITERATURE REVIEW
The Supplement includes a systematic literature review on CYP2C9, VKORC1, CYP4F2 and other relevant genes/genotypes that have been associated with warfarin dosing. This systematic review forms the basis for the recommendations contained in this guideline. Although some of these genes have also been associated with dose of other coumarin anticoagulants, the recommendations below are specific to warfarin.
DRUG: WARFARIN
Warfarin (Coumadin® and others) is the most commonly used oral anticoagulant worldwide, with annual prescriptions in the Western world typically equaling 0.5 to 1.5% of the population (2) . It is prescribed for treatment and prevention of thromboembolic disorders (3) . Although highly efficacious, warfarin dosing is notoriously challenging due to its narrow therapeutic index and wide inter-individual variability in dose requirements even among patients with the same target INR (4) . Complications from inappropriate warfarin dosing are among the most frequently reported adverse events to the U.S. Food and Drug Administration (FDA) and one of the most common reasons for emergency room visits (5) .
Warfarin is usually dosed empirically: an initial dose is prescribed, typically followed by at least weekly measurement of the INR and subsequent dose adjustment. The initial dose is often based on population averages (e.g., 4-5 mg/day), but in some settings, it is common to use loading doses during the first few days of anticoagulation. Irrespective of the method used to initiate warfarin, stable doses to achieve an INR of 2-3 range from 1 to 20 mg/day. The iterative process to define the appropriate dose can take weeks to months and during this period, patients are at increased risk of over-or under-anticoagulation, and thus risk of bleeding or thromboembolism.
Warfarin pharmacology and pharmacokinetics. Figure 1 highlights key elements of warfarin pharmacology and pharmacokinetics. Warfarin inhibits vitamin K epoxide reductase complex (6) and is administered as a racemic mixture, with S-warfarin being more potent than R-warfarin (3).
GENES: CYP2C9, VKORC1 AND CYP4F2
There is substantial candidate gene literature evaluating associations with warfarin dose requirements, as well as several reported genome-wide association studies (Supplemental Tables S1-S7 ). The genes with the strongest literature support, and for which we make recommendations for use in warfarin dosing, are CYP2C9, VKORC1 and CYP4F2. Additionally, genome-wide association studies have identified an independently significant single nucleotide polymorphism (SNP) in the CYP2C cluster (7), which has also been incorporated into this updated recommendation.
CYP2C9 and warfarin
CYP2C9 is a hepatic drug-metabolizing enzyme in the cytochrome P450 (CYP450) superfamily (8) , and is the primary metabolizing enzyme of S-warfarin (Figure 1) . CYP2C9 has over 60 known variant alleles (http://www.cypalleles.ki.se/cyp2c9.htm; CYP2C9 allele definition table (9)). Individuals homozygous for the reference CYP2C9 allele (CYP2C9*1) have the "normal metabolizer" phenotype. Each named CYP2C9 star (*) allele is defined by one or more specific SNPs and to date, and 18 alleles have been associated with decreased enzyme activity (CYP2C9 allele definition table-(9)). The two most common decreased function alleles among individuals of European ancestry are CYP2C9*2 (c.430C>T; p.Arg144Cys; rs1799853) and CYP2C9*3 (c.1075A>C; p.Ile359Leu; rs1057910) (8) . CYP2C9 allele frequencies differ between racial/ethnic groups (8, 10) .
In vitro and in vivo studies suggest CYP2C9*2 and *3 impair metabolism of S-warfarin by ~30-40% and ~80-90%, respectively (8) . Compared to patients homozygous for CYP2C9*1, individuals who inherit one or two copies of CYP2C9*2 or *3 are at greater risk of bleeding during warfarin therapy (11, 12) , require lower doses to achieve similar levels of anticoagulation, and require more time to achieve a stable INR (11) (Supplemental Table S1 ). Additional CYP2C9 alleles (CYP2C9*5, *6, *8, and *11) are associated with decreased function of the CYP2C9 enzyme and contribute to dose variability. These alleles are found with the highest frequency among those of African ancestry, and collectively are more common than CYP2C9*2 and *3 in that population (CYP2C9 frequency table; (9)).
VKORC1 and warfarin
VKORC1 encodes the vitamin K epoxide reductase protein, the target enzyme of warfarin (6) .
VKORC1 catalyzes the conversion of vitamin K-epoxide to vitamin K, which is the rate-limiting step in vitamin K recycling (13) .
A common variant upstream of VKORC1 (c.-1639G>A, rs9923231) is significantly associated with warfarin sensitivity and patients with one or two -1639A require progressively lower warfarin doses than -1639G/G homozygotes (10, (14) (15) (16) (17) (18) . The -1639G>A polymorphism is present on a haplotype that affects VKORC1 protein expression. (18) .
Other common VKORC1 SNPs or haplotypes do not further improve warfarin dose prediction (10, 16) . The c.-1639G>A allele frequency varies among different ancestral populations (VKORC1 frequency table; (19)), and largely explains the differences in average dose requirements between whites, blacks and Asians (10, 17) . Several rare non-synonymous VKORC1 variants confer warfarin resistance (high dose requirements) and are detailed in Supplemental Table S2 (20) .
CYP4F2 and warfarin
CYP4F2 is a primary liver vitamin K oxidase that catalyzes the metabolism of vitamin K to hydroxy-vitamin K1 and removes vitamin K from the vitamin K cycle (21) (Figure 1) . It acts as an important counterpart to VKORC1 in limiting excessive accumulation of vitamin K. The nonsynonymous variant CYP4F2*3 (c.1297G>A; p.Val433Met; rs2108622) was first shown to affect enzyme activity and associated with warfarin dose in three independent white cohorts (22) (23) (24) . Furthermore, including this CYP4F2 variant in warfarin dosing models that included CYP2C9, VKORC1 and clinical factors improved the accuracy of dose prediction (25) . This correlation has been confirmed in subsequent studies with those of European and Asian ancestry, though not those of African ancestry (26, 27) . Two large meta-analyses (one in Han Chinese that pulled in substantial Chinese literature) provide the best estimates for the influence data of CYP4F2*3 on warfarin dose requirements (26, 27) . They suggest statistically significant but modest impacts of 8-11% higher warfarin doses in A allele carriers (Supplemental Table S3 ).
CYP2C rs12777823 and warfarin
rs12777823 is a SNP in the CYP2C cluster near the CYP2C18 gene on chromosome 10 and is associated with a clinically relevant effect on warfarin dose through significant alterations in warfarin clearance, independent of CYP2C9*2 and *3 (7) . This association was first identified through a genome-wide association study in African Americans (p=1.51x10 -8 ) and confirmed in a replication cohort (p=5.04×10 −5 ); meta-analysis of the two cohorts together produced a p value of 4.5 ×10 −12 . This study concluded that African Americans who are heterozygous or homozygous for the rs12777823 A allele require a dose reduction of ~ 7 or 9 mg/week, respectively (7) . Regression analysis showed that addition of this SNP improves the dosing algorithm published by the International Warfarin Pharmacogenetics Consortium (IWPC) by
21%. Further studies have demonstrated the importance of this SNP in African Americans (28) .
Although this variant is common in other ethnic populations, an association with warfarin dose has only been detected among African Americans suggesting it is not the underlying cause but likely inherited with other variant(s) on a haplotype that influences warfarin dose in this population. Of note, an association was not observed in a cohort of Egyptians, thus it is not possible to make broad statements about this allele in people of continental African ancestry.
Most African Americans are of West African ancestry; it is unknown whether similar associations are present in individuals from other parts of Africa.
Genetic Test Interpretation

CYP2C9.
Clinical laboratories typically report CYP2C9 genotype results using the star (*) allele nomenclature system and an interpretation that includes a predicted metabolizer phenotype.
Most FDA-approved CYP2C9 tests include only *2 and *3, which is not as informative for
African ancestry populations; however, some clinical laboratories may offer expanded CYP2C9 panels validated as laboratory developed tests (LDTs) (for allele frequencies see: CYP2C9
frequency table (9)). 
VKORC1. Clinical laboratories typically report
Genetic test options
Commercially available genetic testing options change over time. Additional information about pharmacogenetic testing can be found at the Genetic Testing Registry (http://www.ncbi.nlm.nih.gov/gtr/).
Incidental findings
No diseases have been linked to common CYP2C9 variants independent of drug metabolism and response. Similarly, no diseases have been consistently linked to common VKORC1 and CYP4F2 variants that are interrogated in warfarin response tests. However, homozygosity for rare coding mutations in VKORC1 are a known cause of combined deficiency of vitamin K-dependent clotting factors-2 (VKCFD2), which is a rare and potentially fatal bleeding disorder that can be reversed by oral administration of vitamin K (29) .
Linking genetic variability to variability in drug-related phenotypes
Common variants in CYP2C9, VKORC1, and CYP4F2 account for up to 18%, 30%, and 11%
respectively, of the variance in stable warfarin dose among patients of European ancestry (10, 16, 17, 30, 31) , but because of differing allele frequencies across populations, these variants explain less of the dose variability in patients of other ancestries. In particular, CYP2C9*2 is virtually absent in Asians, and additional CYP2C9 alleles (e.g. *5, *6, *8, and *11 alleles) occur almost exclusively in persons of African ancestry and contribute to dose variability in this population. Other genes of potential importance are discussed in the Supplemental Material.
Published in 2013, the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) and
Clarification of Optimal Anticoagulation through Genetics (COAG) trials examined the efficacy of genotype-guided warfarin dosing in randomized controlled trials (32, 33) . In a homogenous
European population, the EU-PACT trial showed shorter time to stable dose, improved percent time in therapeutic range, and reduced number of episodes with an INR>4 using a pharmacogenetic dosing algorithm compared to standard dosing (33 The Genetics-InFormatics Trial (GIFT) is an on-going randomized controlled trial examining the effectiveness and safety of genotype-guided dosing in orthopedic patients with composite endpoints for symptomatic and asymptomatic venous thromboembolism, major hemorrhage, INR ≥ 4, and death (35) . GIFT includes genotyping for CYP2C9*2 and *3, CYP4F2*3, and VKORC1-1639, but does not include the African-specific CYP2C9 alleles or rs12777823. At the time of this publication, results from the GIFT trial were not available.
Therapeutic Recommendations: Adults
Recommendations for warfarin maintenance (chronic) dosage based on genetic information.
We use the three-tiered rating system described previously (and in Supplemental Material) (1) in which ratings of strong, moderate, and optional are applied based on the evidence reviewed.
The recommendations for dosing based on genotype contained herein include recommendations and are derived from numerous observational and prospective studies, and randomized trials that suggest the ability to more accurately identify stable therapeutic warfarin dose requirements through use of both genetic and clinical information. Data from prospective studies and randomized controlled trials are equivocal on whether the improvement in dosing prediction by pharmacogenetics dosing leads to improved clinical outcomes. The majority of the literature underpinning these guidelines arises from individuals of European ancestry, African Americans, and East Asians. However, the more limited literature in other populations generally suggests the guidelines are appropriate in them also.
Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose (16, 17, 36, 37) . Two algorithms perform well in estimating stable warfarin dose (16, 17) and were created using more than 5000 subjects, though as noted above, more recent data suggest they do not perform acceptably in African Americans when used without modification for CYP2C9 alleles frequently found in the African population (32) . The Gage and IWPC algorithms or minor adjustments to them have also been the algorithms used in both randomized controlled trials and most of the prospective dosing studies. Dosing algorithms using genetic information outperform non-genetic clinical algorithms and fixed-dose approaches in dose prediction, except in African Americans when the algorithm only includes CYP2C9*2 and *3 (16, 17, 32) . Genetics-based algorithms also better predict warfarin dose than the FDAapproved warfarin label table (38) .
Pharmacogenetic algorithm-based warfarin dosing. This guideline recommends that pharmacogenetic warfarin dosing be accomplished through the use of one of the pharmacogenetic dosing algorithms described above, as summarized in Figure 2 . These algorithms, as originally published, are available in the Supplement and the dosing algorithm published by IWPC is also online at http://www.pharmgkb.org/do/serve?objId=PA162372936&objCls=Dataset#tabview=tab2. The two algorithms provide very similar dose recommendations. The clinical and genetic information used in one or both algorithms is shown in box 1. These algorithms compute the anticipated stable daily warfarin dose to one decimal and the clinician must then prescribe a regimen (e.g., an estimate of 4.3 mg/day might be given as 4 mg daily except 5 mg two days per week). An additional "dose revision" algorithm, that can be used on days 4-5 of therapy for dose refinement and uses genetic information, was tested in COAG and EU-PACT and can also be used (36) (Supplemental Table S5 ).
It is important to note that these algorithms do not include CYP4F2, CYP2C9*5, *6, *8, or *11 or rs12777823, and incorporation of these should be added when results are available, as described in Figure 2 . Thewarfarindosing.org website contains both algorithms, the Gage algorithm (16) as the primary algorithm and the IWPC algorithm (17) as the secondary algorithm and can adjust for CYP4F2, CYP2C9*5 and *6. If utilizing warfarindosing.org, the user should be clear on whether the algorithm is or is not incorporating genotypes beyond CYP2C9 *2 and *3
and VKORC1, which are the only three genotypes in the original version of both algorithms.
Pharmacogenetics-informed loading (or initiation) dose calculations.
The use of a different initial warfarin dose (or "loading dose") is somewhat controversial and plays different roles in different regions of the world, based on experience and local standards. A dosing tool that can be used in children of European ancestry is available at http://www.warfarindoserevision.com (43) .
Other considerations
Given the effects of CYP2C9 on warfarin clearance, and given that the CYP2C9 variant alleles Material also discusses incorporation of genetic information into the initial dose, and alternatives to warfarin.
POTENTIAL BENEFITS AND RISKS FOR THE PATIENT
Incorporation of genetic information has the potential to shorten the time to stable INR, increase the time within the therapeutic INR range, and reduce under-dosing or over-dosing during the initial treatment period (33) . If these benefits are achieved, they could result in a reduced risk of bleeding and thromboembolic events (12, 45) . There are also potential risks. For example, using genetic information to guide dosing may lead to false security and inadequate INR monitoring.
In particular, there are risks of using pharmacogenetic dosing in those of African ancestry if only CYP2C9 *2 and *3 alleles are included. Genetic-guided dosing may increase the risk for overdosing or under-dosing, especially in individuals who carry rare or untested variants and are assigned as "wild-type" by default (17, 32) . The cost-benefit of genetic-guided therapy depends on the cost of genotyping and the reduction in adverse events (46) 
